About AVT
Browse Articles
Customer Services

Case report

Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient

Sarita D Boyd, Frank Maldarelli, Irini Sereti, G Laissa Ouedraogo, Catherine A Rehm, Valerie Boltz, Diana Shoemaker, Alice K Pau

Corresponding author name: Sarita D Boyd
Corresponding author e-mail: sarita.boyd@fda.hhs.gov

Citation: Antiviral Therapy 2011; 16:257-261
doi: 10.3851/IMP1749

Date accepted: 16 January 2010
Date published online: 04 March 2011


Here, we describe an HIV-infected patient with pretreatment resistance to raltegravir, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, and the ultimate ability to achieve viral suppression. Pretreatment integrase resistance testing is not routinely performed because transmitted integrase mutations conferring resistance to raltegravir are currently thought to be negligible. We suggest obtaining a pretreatment integrase genotype in patients with transmitted multiclass drug resistance in order to create an optimal first regimen and increase the chance for virological suppression.


Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.